Cough in Idiopathic Pulmonary Fibrosis Market Size in the 7MM reached approximately USD 154 million in 2022 and It is expected to grow by 2034, estimates DelveInsight

DelveInsight's "Cough in Idiopathic pulmonary fibrosis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Cough in Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology and the Cough in Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover about the Cough in Idiopathic Pulmonary Fibrosis market report @ https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-ipf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Some of the key facts of the Cough in Idiopathic Pulmonary Fibrosis Market Report
• As per DelveInsight's estimations, the total Cough in Idiopathic Pulmonary Fibrosis diagnosed prevalent cases in the 7MM were approximately 148 thousand cases in 2022 and are projected to increase during the forecast period.
• The overall count of individuals diagnosed with IPF in the United States was approximately 95 thousand in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
• Among the 7MM, the US accounted for nearly 76 thousand diagnosed prevalent cases of Cough in Idiopathic Pulmonary Fibrosis, and these cases are expected to increase during the forecast period (2023-2034).
• Among EU4 and the UK, the UK had the highest diagnosed prevalent population of Cough in Idiopathic Pulmonary Fibrosis, with about 13 thousand cases, followed by France and Italy in 2022. On the other hand, Germany had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
• In Japan, there were around 17 thousand diagnosed prevalent cases of Cough in Idiopathic Pulmonary Fibrosis in 2022. These cases are expected to increase at a significant CAGR.
• The leading Cough in IPF Companies such as NeRRe Therapeutics, Trevi Therapeutics, Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, Cellular Sciences, Emphycorp, and others.
• Promising Cough in IPF Therapies such as Orvepitant Maleate, Haduvio (nalbuphine ER), among others.

Stay ahead in the competitive landscape of the Cough in Idiopathic Pulmonary Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-ipf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cough in Idiopathic Pulmonary Fibrosis Epidemiology Segmentation in the 7MM
• Total Cough in Idiopathic Pulmonary Fibrosis Diagnosed Prevalent Cases

Download the report to understand which factors are driving Cough in Idiopathic Pulmonary Fibrosis epidemiology trends @ https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-ipf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Emerging Cough in Idiopathic Pulmonary Fibrosis Drugs
• Orvepitant Maleate: NeRRe Therapeutics
Orvepitant Maleate, developed by NeRRe Therapeutics, is a novel, selective NK-1 receptor antagonist. It blocks substance P effects, reducing central neural hypersensitivity and addressing chronic cough through peripherally and centrally targeted mechanisms. After demonstrating proof of efficacy in patients with RCC or UCC, NeRRe is currently conducting Phase II trials to evaluate the effect of two doses of orvepitant in chronic cough with IPF.

• Haduvio (nalbuphine ER): Trevi Therapeutics
Haduvio (nalbuphine ER) is under clinical development by Trevi Therapeutics and is currently in Phase II for Cough in Idiopathic Pulmonary Fibrosis treatment. Administered orally, it is an extended-release, mixed ?-opioid receptor agonist and μ-opioid receptor antagonist.

Cough in Idiopathic Pulmonary Fibrosis Market Outlook
Cough, a predominant and distressing symptom in IPF, significantly compromises patients' quality of life, prompting a pressing need for effective interventions tailored to this aspect of the disease. Despite approved therapies for IPF, there is not an established treatment specifically targeting the associated cough. Current therapeutic strategies for IPF-related cough fall into two categories: those suppressing the cough reflex and those targeting IPF pathology. Yet, agents like dextromethorphan and opioids exhibit limited efficacy and systemic side effects, hindering widespread use. Traditional IPF medications, pirfenidone, and nintedanib, mainly focus on disease progression without extensive studies on managing IPF-related cough.

Discover the future of Cough in Idiopathic Pulmonary Fibrosis Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-ipf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cough in Idiopathic Pulmonary Fibrosis Companies
NeRRe Therapeutics, Trevi Therapeutics, Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, Cellular Sciences, Emphycorp, and others.

Scope of the Cough in Idiopathic Pulmonary Fibrosis Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Key Cough in Idiopathic Pulmonary Fibrosis Companies: NeRRe Therapeutics, Trevi Therapeutics, Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, Cellular Sciences, Emphycorp, and others
• Cough in Idiopathic Pulmonary Fibrosis Therapies: Orvepitant Maleate, Haduvio (nalbuphine ER), and others.
• Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Cough in Idiopathic Pulmonary Fibrosis current marketed and Cough in Idiopathic Pulmonary Fibrosis emerging therapies
• Cough in Idiopathic Pulmonary Fibrosis Market Dynamics: Cough in Idiopathic Pulmonary Fibrosis market drivers and Cough in Idiopathic Pulmonary Fibrosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Cough in Idiopathic Pulmonary Fibrosis Unmet Needs, KOL's views, Analyst's views, Cough in Idiopathic Pulmonary Fibrosis Market Access and Reimbursement

Got queries? Click here to know more about the Cough in Idiopathic Pulmonary Fibrosis market Landscape @ https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-ipf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Cough in Idiopathic Pulmonary Fibrosis Patient Share (%) Overview at a Glance
5. Cough in Idiopathic Pulmonary Fibrosis Market Overview at a Glance
6. Cough in Idiopathic Pulmonary Fibrosis Disease Background and Overview
7. Cough in Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Cough in Idiopathic Pulmonary Fibrosis
9. Cough in Idiopathic Pulmonary Fibrosis Current Treatment and Medical Practices
10. Unmet Needs
11. Cough in Idiopathic Pulmonary Fibrosis Emerging Therapies
12. Cough in Idiopathic Pulmonary Fibrosis Market Outlook
13. Country-Wise Cough in Idiopathic Pulmonary Fibrosis Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Cough in Idiopathic Pulmonary Fibrosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.